NGM Biopharmaceuticals Inc (NGM) has released an update.
NGM Biopharmaceuticals, Inc. was notified by Nasdaq on January 18, 2024, that it has regained compliance with the minimum bid price requirement after its common stock’s closing bid price remained at $1.00 or above from January 2 to January 17, 2024. Consequently, the issue concerning its non-compliance with Nasdaq Listing Rule 5450(a)(1) has been resolved and the matter is closed.
For further insights into NGM stock, check out TipRanks’ Stock Analysis page.
